
TriSalus Life Sciences fell 34.3% from $4.34 to $2.85, behind the S&P 500's +9.8%. Its worst day was May 13 (−41.4%), and its low came May 14 at $2.52.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.96 missed the $-0.17 estimate on $11.6M revenue (est. $11.6M); FY revenue guidance of $44.1M against the $45.0M consensus.
+3.9% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
TriSalus Life Sciences shares rose 13.3%, while the S&P 500 rose 0.9%.
+13.3% · S&P 500 +0.9%
TriSalus Life Sciences closed at its highest level of the year, 72.8% above where the year started.
+3.4% · S&P 500 +0.2%
TriSalus Life Sciences shares rose 18.2%, while the S&P 500 rose 0.7%.
+18.2%, the year's best day · S&P 500 +0.7%
EPS of $-0.21 missed the $-0.13 estimate on $13.2M revenue (est. $13.0M); FY revenue guidance of $60.0M–$62.0M against the $54.1M consensus.
−6.4% · S&P 500 −1.3%
EPS of $0.03 beat the $-0.16 estimate on $8.9M revenue (est. $10.5M); FY revenue guidance of $54.0M–$57.0M against the $59.7M consensus.
−41.4%, the year's worst day, on 7M shares, the year's heaviest volume · S&P 500 +0.6%
EPS of $-0.16 missed the $-0.11 estimate on $11.4M revenue (est. $10.3M); FY revenue guidance of $54.0M–$57.0M against the $52.4M consensus.
+15.2% · S&P 500 +0.6%
EPS of $-0.15 missed the $-0.13 estimate on $12.9M revenue (est. $14.0M); FY revenue guidance of $46.0M–$48.0M against the $53.6M consensus.
−11.5% · S&P 500 −0.4%
Where it ended: a close of $2.85 on Nov 10, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.06, revenue est. $19.3M).
Nothing in the past 12 months.
All TLSI dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TLSI and SPY from Benzinga historical bars. Not investment advice.